October 2021

Randomized controlled trial published in American Journal of Psychiatry finds individually targeted neurostimulation relieved severe depression in 79% of people receiving active treatment BURLINGAME, Calif., Oct. 29, 2021 — Magnus Medical, Inc., a medical device company, today announced that the U.S. Food & Drug Administration...